Lv1
100 积分 2024-09-12 加入
Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
1天前
求助中
Cost Effectiveness of Tremelimumab Plus Durvalumab for Unresectable Hepatocellular Carcinoma in the USA
1天前
求助中
HTA28 A Comparative Review of Pharmacoeconomic (PE) Guidelines in ASIA-Pacific (APAC) with Europe and North America
1个月前
已完结
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study
2个月前
已完结
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study[J]. Lancet Respir Med
2个月前
已完结
皖公网安备34019202002308
